When was Oxurion founded?

Oxurion was founded in 1991 and raised its 1st funding round 26 years after it was founded.

Where is Oxurion located?

Oxurion is headquartered in Leuven, Belgium.

How many employees does Oxurion have?

As of Mar 31, 2026, the latest employee count at Oxurion is 32.

Is Oxurion a funded company?

Oxurion is a funded company, having raised an undisclosed amount across 4 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jan 01, 2017.

When was the latest funding round of Oxurion?

Oxurion's latest funding was a $***** Post IPO round on Mar 02, 2023, with participation from 1 investor.

What is the annual revenue of Oxurion?

Annual revenue of Oxurion is €2.95K as on Dec 31, 2024.

Where does Oxurion rank among its competitors?

Oxurion ranks 851st amongst 2627 active competitors, of which 902 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Erasca, which secured $45M in Mar, 2024.

Who are the top competitors of Oxurion?

Oxurion's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Juno Therapeutics. Among them, Erasca secured the most recent funding round in March, 2024.

Oxurion - 2026 Company Profile, Funding, Competitors & Financials

Oxurion is a public company based in Leuven (Belgium), founded in 1991. It operates as a Developer of therapies for treating ophthalmic disorders. Oxurion has raised an undisclosed amount in funding. The company has 2627 active competitors, including 902 funded and 667 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Juno Therapeutics.

Company Details

Developer of therapies for treating ophthalmic disorders. The lead candidate of the company is single intravitreal injection of THR-149, a novel PKal inhibitor, of 3 ascending dose levels in subjects with visual impairment.

Website: oxurion.com
Social
Phone Number: +32 **********

Key Metrics

Founded Year

1991

Location

Leuven, Belgium

Stage

Public

Latest Funding Round

Post IPO, Mar 02, 2023, $*****

Investors

Pontifax & 3 more

Ranked

851^st among 2627 active competitors

Annual Revenue

€2.95K as on Dec 31, 2024

Employee Count

32 as on Mar 31, 2026

Investment & Acquisitions

Axiodis

Similar Companies

Apellis Pharmaceuticals & 281 more

Exit Details

Public

View Oxurion's full profile

Oxurion is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Oxurion CIN: 0881.620.924 , Belgium, Active	May 29, 2006	$3.2K (As on Dec 31, 2024)	22 (As on Dec 31, 2022)	-

Oxurion got listed on Jul 07, 2006.

Click here to take a look at Oxurion's IPO in detail

Oxurion has raised funding over 4 rounds. Its first funding round was on Jan 01, 2017. Its latest funding round was a Post IPO round on Mar 02, 2023 for $*****. 1 investor participated in its latest round. Oxurion has 4 institutional investors.

Here is the list of recent funding rounds of Oxurion:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 02, 2023	4419146	Post IPO	3579552	8522365	7960025	8713519
Nov 22, 2021	7940301	Post IPO	8692786	4446581	7879527	Pontifax & 1 more
Jan 01, 2020	4350330	Grant (prize money)	2516565	9891580	2350511	Europa

Access funding benchmarks and valuations. Sign up today!

View details of Oxurion's funding rounds and investors

Oxurion's employee count trend

Oxurion has 32 employees as of Mar 26. Here is Oxurion's employee count trend over the years:

Uncover Oxurion's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Oxurion include Jazz Pharmaceuticals, Sana Biotechnology and Juno Therapeutics. Here is the list of Top 10 competitors of Oxurion, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
3rd	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, RA Capital Management & 14 others	74/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
6th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
7th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
8th	Harbour BioMed 2016, Shanghai (China), Public	Developer of antibody therapeutics in immunology and oncology disease	$313M	Hudson Bay Capital, GIC & 19 others	71/100
9th	iTeos Therapeutics 2011, Cambridge (United States), Acquired	Developer of immunotherapy for treating cancer	$204M	Boxer Capital, RA Capital Management & 19 others	70/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	70/100
851st	Oxurion 1991, Leuven (Belgium), Public	Developer of therapies for treating ophthalmic disorders	-	Pontifax, Kreos Capital & 2 others	45/100